DURAVYU Vorolanib Phase III Wet AMD — PatSnap Eureka
DURAVYU Vorolanib Phase III: Sustained-Release TKI vs. Anti-VEGF Competition
EyePoint Pharmaceuticals' DURAVYU (vorolanib/EYP-1901) is a sustained-release intravitreal implant delivering a tyrosine kinase inhibitor to treat wet age-related macular degeneration — positioning it as a potential challenger to biologic anti-VEGF standards including faricimab (Vabysmo). Explore the mechanism, competitive landscape, and IP signals with PatSnap Eureka.
Wet AMD Treatment Modalities by Delivery Format
Approved biologics rely on repeated injections; DURAVYU's sustained-release implant targets a distinct delivery paradigm.
How DURAVYU's TKI Approach Differs from Anti-VEGF Biologics
Wet age-related macular degeneration is driven by pathological choroidal neovascularization — abnormal blood vessel growth beneath the retina — mediated primarily by VEGF and related angiogenic pathways. Standard-of-care biologics such as ranibizumab, aflibercept, and faricimab (Vabysmo) neutralise VEGF proteins extracellularly via intravitreal injection, requiring repeated clinic visits.
DURAVYU (vorolanib, formerly EYP-1901) takes a fundamentally different approach. As a small-molecule tyrosine kinase inhibitor (TKI), vorolanib inhibits VEGF receptor signalling intracellularly — downstream of the receptor — rather than blocking the VEGF ligand itself. This small molecular size is critical: it enables formulation into EyePoint's sustained-release intravitreal implant platform, designed to deliver therapeutic drug concentrations over extended intervals from a single administration.
Faricimab (Vabysmo), developed by Roche/Genentech, represents the most advanced biologic competitor — it uniquely targets both VEGF-A and Ang-2 pathways simultaneously, extending dosing intervals compared to earlier anti-VEGF agents. DURAVYU's competitive thesis is not necessarily superior efficacy per injection, but rather a reduction in total injection burden through sustained drug release from its implant.
Understanding these mechanistic distinctions is central to evaluating the IP landscape and clinical trial strategy for both assets. The PatSnap Eureka patent analytics platform enables researchers to map assignee filing strategies, freedom-to-operate risks, and formulation IP across the sustained-release ophthalmic space.
DURAVYU vs. Vabysmo and the Anti-VEGF Standard of Care
A head-to-head comparison of mechanism, delivery format, molecular target, and competitive positioning across the leading wet AMD therapeutic approaches.
| Attribute | DURAVYU (Vorolanib) | Vabysmo (Faricimab) | Eylea (Aflibercept) | Lucentis (Ranibizumab) |
|---|---|---|---|---|
| Developer | EyePoint Pharmaceuticals | Roche / Genentech | Regeneron / Bayer | Novartis / Genentech |
| Molecule Type | Small-molecule TKI Implant | Biologic antibody | Fusion protein | Monoclonal antibody fragment |
| Molecular Target | VEGFR (intracellular TKI) | VEGF-A + Ang-2 Dual | VEGF-A + PlGF | VEGF-A |
| Delivery Format | Sustained-release intravitreal implant SR | Intravitreal injection | Intravitreal injection | Intravitreal injection |
| Mechanism | Intracellular VEGFR kinase inhibition | Extracellular VEGF-A + Ang-2 neutralisation | Extracellular VEGF-A / PlGF decoy | Extracellular VEGF-A neutralisation |
| Clinical Stage | Phase III (wAMD) | Approved (wAMD, DME) | Approved (wAMD, DME) | Approved (wAMD) |
Track EyePoint vs. Vabysmo patent activity in real time
PatSnap Eureka monitors assignee filings, claim scope, and competitive IP moves across the wAMD space.
Sustained-Release Ophthalmic Drug Delivery: Key Data Signals
Visualising the mechanistic and competitive dimensions of the DURAVYU vs. anti-VEGF landscape using patent and literature intelligence from PatSnap Eureka.
Anti-VEGF Pathway Targets Across wAMD Agents
Comparative mapping of molecular pathway coverage: from single-target VEGF-A biologics to dual-pathway faricimab and intracellular TKI vorolanib.
EyePoint vs. Vabysmo: Head-to-Head Attribute Comparison
Direct comparison of DURAVYU (vorolanib) and faricimab (Vabysmo) across five key competitive dimensions relevant to wAMD clinical and IP strategy.
IP and Clinical Strategy: What the Landscape Signals
Key strategic dimensions for R&D teams, IP professionals, and investors tracking DURAVYU and the wAMD sustained-delivery space.
Sustained-Release Formulation IP is the Core Moat
For DURAVYU, the competitive advantage lies not only in vorolanib's TKI mechanism but in EyePoint's sustained-release intravitreal implant technology. Formulation patents covering drug-polymer matrices, implant geometry, and release kinetics represent the primary IP barrier to entry. PatSnap's analytics platform enables systematic mapping of these formulation claims against potential generic or biosimilar entrants.
Small-Molecule TKI Enables Formulation Flexibility Biologics Cannot Match
Biologic anti-VEGF agents such as faricimab are large proteins that cannot be incorporated into conventional sustained-release polymer implants without stability challenges. Vorolanib's small-molecule nature is the enabling property for EyePoint's implant approach — a structural advantage that biologics competing in wAMD cannot replicate without fundamental reformulation. This creates a distinct IP space for ophthalmic small-molecule formulation chemistry.
Intelligence Tools for the Wet AMD Competitive Landscape
PatSnap Eureka provides R&D teams, IP professionals, and drug developers with the tools to navigate the DURAVYU, vorolanib, and anti-VEGF patent and clinical landscape.
Vorolanib & EYP-1901 Assignee Mapping
Search across 2B+ patent records to identify all EyePoint Pharmaceuticals filings related to vorolanib, EYP-1901, and sustained-release intravitreal implant technology. Track claim scope evolution from early formulation filings to Phase III-stage composition-of-matter claims.
2B+ patent recordsRoche / Faricimab IP Monitoring
Monitor Roche and Genentech's patent activity around faricimab (Vabysmo), including Ang-2 pathway claims, formulation filings, and method-of-treatment patents. Set alerts for new publications from key assignees in the wAMD biologic space across 120+ jurisdictions.
120+ jurisdictionsPhase III Trial & Literature Analysis
Cross-reference patent filings with clinical trial registrations and published literature for DURAVYU Phase III programmes. Identify which patent claims are being validated by clinical data and where regulatory strategy aligns with IP protection timelines in the wAMD indication.
Patents + literature cross-referenceSustained-Release Ophthalmic FTO Analysis
Identify freedom-to-operate risks for sustained-release intravitreal delivery platforms. Map the landscape of polymer matrix, implant geometry, and drug release kinetics patents that could affect generic or next-generation entrants to the wAMD sustained-delivery space. Explore how PatSnap customers use Eureka for FTO workflows.
FTO risk mappingDURAVYU Vorolanib Wet AMD — Key Questions Answered
DURAVYU (vorolanib, formerly EYP-1901) is a sustained-release intravitreal implant developed by EyePoint Pharmaceuticals that delivers a tyrosine kinase inhibitor (TKI) to treat wet age-related macular degeneration (wAMD). Rather than blocking VEGF proteins directly like biologic anti-VEGF agents, vorolanib inhibits VEGF receptor signalling intracellularly, aiming to suppress pathological choroidal neovascularization over an extended period from a single implant.
Vabysmo (faricimab) is a biologic anti-VEGF antibody administered by repeated intravitreal injections that targets both VEGF-A and Ang-2 pathways. DURAVYU is a sustained-release intravitreal implant delivering a small-molecule TKI (vorolanib), designed to reduce injection frequency by providing durable drug levels from a single administration. The two agents differ in mechanism (biologic vs. small-molecule TKI), dosing format (periodic injection vs. sustained implant), and molecular targets.
Wet AMD driven by pathological choroidal neovascularization requires ongoing suppression of VEGF-mediated angiogenic pathways. Current standard-of-care biologics require frequent intravitreal injections, creating a significant treatment burden for patients and clinicians. Sustained-release platforms like DURAVYU aim to maintain therapeutic drug concentrations over extended intervals, potentially reducing injection frequency while preserving visual outcomes — a key unmet need in the wAMD indication.
Wet AMD is primarily mediated by pathological choroidal neovascularization driven by VEGF and related angiogenic pathways. Leading approved therapies target VEGF-A (ranibizumab, bevacizumab, aflibercept) or dual VEGF-A and Ang-2 pathways (faricimab/Vabysmo). Investigational small-molecule TKIs such as vorolanib target VEGF receptor tyrosine kinase signalling intracellularly, representing a distinct mechanistic approach to the same angiogenic cascade.
EyePoint Pharmaceuticals (DURAVYU/vorolanib) competes in the wet AMD sustained-delivery space against established anti-VEGF biologics including Roche/Genentech's faricimab (Vabysmo), Regeneron's aflibercept (Eylea), and Novartis's ranibizumab (Lucentis). Other sustained-delivery approaches under investigation include port delivery systems and other intravitreal implant technologies. The competitive landscape is defined by injection frequency reduction, durability of visual acuity gains, and safety profiles.
A tyrosine kinase inhibitor (TKI) is a small molecule that blocks the intracellular signalling activity of receptor tyrosine kinases, including VEGF receptors (VEGFR-1, VEGFR-2). In wet AMD, VEGF binding to its receptors drives choroidal neovascularization. TKIs like vorolanib interrupt this signalling cascade downstream of the receptor, offering a small-molecule alternative to anti-VEGF biologics that block VEGF proteins extracellularly. Their small molecular size also enables formulation into sustained-release implants.
Still have questions about vorolanib, wAMD, or the anti-VEGF patent landscape? Let PatSnap Eureka answer them instantly.
Ask PatSnap Eureka About VorolanibMap the DURAVYU and Anti-VEGF Patent Landscape Instantly
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D intelligence across ophthalmology and beyond.
References
- National Institutes of Health (NIH) — VEGF and Choroidal Neovascularization in AMD
- U.S. Food and Drug Administration (FDA) — Ophthalmology Drug Approvals and Clinical Trial Guidance
- Roche — Vabysmo (Faricimab) VEGF-A and Ang-2 Dual Pathway Mechanism
- World Health Organization (WHO) — Age-Related Macular Degeneration Global Burden
- ClinicalTrials.gov — EyePoint Pharmaceuticals DURAVYU (EYP-1901 / Vorolanib) Phase III wAMD Registrations
- PatSnap — Innovation Intelligence Platform: Ophthalmic Drug Delivery Patent Analytics
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Mechanism descriptions and competitive positioning are derived from publicly available patent filings, clinical trial registrations, and peer-reviewed literature.
PatSnap Eureka searches patents and research to answer instantly.